Get the Stockscreener App
3.50
3.86%
0.13
After Hours:
3.61
0.11
+3.14%
Niagen Bioscience Inc stock is traded at $3.50, with a volume of 950.92K.
It is up +3.86% in the last 24 hours and down -5.41% over the past month.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
See More
Previous Close:
$3.37
Open:
$3.42
24h Volume:
950.92K
Relative Volume:
1.10
Market Cap:
$278.76M
Revenue:
$130.42M
Net Income/Loss:
$18.64M
P/E Ratio:
16.04
EPS:
0.2182
Net Cash Flow:
$4.05M
1W Performance:
+2.04%
1M Performance:
-5.41%
6M Performance:
-46.15%
1Y Performance:
-74.60%
1-Day Range:
$3.40
$3.53
1-Week Range:
$3.355
$3.575
52-Week Range:
$3.35
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Name
Niagen Bioscience Inc
Sector
Industry
Phone
310-388-6706
Address
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
3.50 | 268.40M | 130.42M | 18.64M | 4.05M | 0.2182 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Initiated | Canaccord Genuity | Buy |
| Aug-16-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-11-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Mar-08-22 | Initiated | ROTH Capital | Buy |
| Oct-16-19 | Initiated | Oppenheimer | Outperform |
| Feb-14-19 | Initiated | B. Riley FBR | Buy |
| Nov-27-17 | Resumed | H.C. Wainwright | Buy |
| Sep-25-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-03-17 | Initiated | Rodman & Renshaw | Buy |
View All
Niagen Bioscience Inc Stock (NAGE) Latest News
Niagen Bioscience Inc (NAGE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Niagen Bioscience Inc (NAGE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Niagen Bioscience Inc (NAGE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Niagen Bioscience Inc (NAGE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Niagen Bioscience Inc (NAGE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Niagen Bioscience And 2 Other Promising Penny Stocks To Watch - simplywall.st
Niagen Bioscience Inc (NAGE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Niagen Bioscience Q1 2026 slides: e-commerce surges 14% amid transition - Investing.com
Earnings call transcript: Niagen Bioscience Q1 2026 sees growth in e-commerce - Investing.com
Assessing Niagen Bioscience (NAGE) Valuation As It Renames Its NAD+ Research Program - Yahoo Finance
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science - Business Wire
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference - Stock Titan
Is Niagen Bioscience’s (NAGE) NAD+ Research Push Quietly Redefining Its Competitive Moat? - simplywall.st
Niagen Bioscience (NAGE) Rebrands Research Program - GuruFocus
Niagen Bioscience renames research program By Investing.com - Investing.com Nigeria
Niagen Bioscience renames research program - Investing.com
Q4 2025 Niagen Bioscience Inc Earnings Call Transcript - GuruFocus
Q1 2026 Niagen Bioscience Inc Earnings Call Transcript - GuruFocus
Q2 2025 Niagen Bioscience Inc Earnings Call Transcript - GuruFocus
Q3 2025 Niagen Bioscience Inc Earnings Call Transcript - GuruFocus
NAGE Stock Price, Quote & Chart | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
CCORF Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Maintains Target Price $10 - Moomoo
NAGE Technical Analysis | Trend, Signals & Chart Patterns | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
National Advertising Review Board Recommends Niagen Modify or Discontinue Certain Tru Niagen NAD+ Dietary Supplement Claims - The Manila Times
National Advertising Review Board Recommends Niagen Modify - GlobeNewswire
NAGE News | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
Niagen Bioscience Earnings Call Highlights Growth Push - TipRanks
How The Niagen Bioscience (NAGE) Story Is Shifting As Price Targets Edge Lower - Yahoo Finance
Is Niagen Bioscience’s (NAGE) Telehealth Niagen Plus Launch a Turning Point in Its Direct-Access Strategy? - simplywall.st
Niagen Bioscience stock price target lowered to $11 by H.C. Wainwright - Investing.com Australia
HC Wainwright Lowers Niagen Bioscience (NASDAQ:NAGE) Price Target to $11.00 - MarketBeat
Assessing Niagen Bioscience (NAGE) Valuation After Earnings Strength And New NAD Plus Delivery Initiatives - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results - Post Register
Will Niagen Bioscience’s (NAGE) Telehealth NAD+ Push Redefine Its Core Therapeutic Focus? - Yahoo Finance
Biotech Innovator Niagen Uncovers Breakthrough NAD+ Booster, Reports Strong Q1 Results - Streetwise Reports
Niagen Bioscience Announces Participation in Upcoming Investor Conferences - PharmiWeb.com
Niagen Bioscience Announces Participation in Upcoming May 2026 Investor Conferences - BioSpace
Niagen Bioscience Q1 2026 slides: e-commerce surges 14% amid transition By Investing.com - Investing.com South Africa
Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs (UPDATED) - Benzinga
Niagen Bioscience reaffirms 10%-15% 2026 growth outlook while increasing marketing spend expectations - MSN
Niagen Bioscience Inc Stock (NAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):